VANCOUVER, BRITISH COLUMBIA, Sep 20, 2010 (MARKETWIRE via COMTEX) – Berkley Resources Inc. ()()() reports it has purchased 200,000 common shares of Vancouver-based TrichoScience Innovations Inc. at a price of CDN$1.00 per share. TrichoScience, a privately-held Life Sciences company, has developed and patented a new hair cell replication technology called Replicel™ that has the potential to become an effective, non-surgical treatment for pattern baldness and other forms of hair loss in both men and women. Berkley’s share purchase represents 2.13% of TrichoScience’s issued and outstanding share capital.
The Replicel™ procedure is based on autologous cell implantation technology that replicates a patient’s hair cells from their own healthy hair follicles. When reintroduced into areas of hair loss, the replicated cells initiate natural hair regeneration. Replicel™ will undergo Stage 1 Human Clinical Trials beginning in late 2010. For more information about TrichoScience and Replicel™ visit www.trichoscience.com.
ABOUT BERKLEY RESOURCES INC.
Berkley is a growth-oriented and diversified venture company pursuing opportunities in both Canada and the United States. The company’s shares trade on the Canadian National Stock Exchange (CNSX) under the symbol BKS and in the U.S. under the symbol BRKDF.
So it is possible to buy shares from TrichoScience?
Someone in this forum wanted to buy stocks of HM companies, but complained that he couldn’t find any company publicly traded (except Aderans, which is traded in Japan).
» http://www.marketwatch.com/story/berkley-resources-purchases-interest-in-trichoscience-innovations-2010-09-20-1630560?reflink=MW_news_stmp
»
» VANCOUVER, BRITISH COLUMBIA, Sep 20, 2010 (MARKETWIRE via COMTEX) –
» Berkley Resources Inc. ()()() reports it has purchased 200,000 common
» shares of Vancouver-based TrichoScience Innovations Inc. at a price of
» CDN$1.00 per share. TrichoScience, a privately-held Life Sciences company,
» has developed and patented a new hair cell replication technology called
» Replicel™ that has the potential to become an effective, non-surgical
» treatment for pattern baldness and other forms of hair loss in both men and
» women. Berkley’s share purchase represents 2.13% of TrichoScience’s issued
» and outstanding share capital.
»
» The Replicel™ procedure is based on autologous cell implantation
» technology that replicates a patient’s hair cells from their own healthy
» hair follicles. When reintroduced into areas of hair loss, the replicated
» cells initiate natural hair regeneration. Replicel™ will undergo Stage 1
» Human Clinical Trials beginning in late 2010. For more information about
» TrichoScience and Replicel™ visit www.trichoscience.com.
»
» ABOUT BERKLEY RESOURCES INC.
»
» Berkley is a growth-oriented and diversified venture company pursuing
» opportunities in both Canada and the United States. The company’s shares
» trade on the Canadian National Stock Exchange (CNSX) under the symbol BKS
» and in the U.S. under the symbol BRKDF.
»
» For more information visit: www.berkleyresources.com.
»
» ON BEHALF OF THE BOARD
»
» Matt Wayrynen, President and Chief Executive Officer
» So it is possible to buy shares from TrichoScience?
» Someone in this forum wanted to buy stocks of HM companies, but complained
» that he couldn’t find any company publicly traded (except Aderans, which is
» traded in Japan).
That was me.
The article says its a private company so how the heck do we buy it?
This is an advertising site for paid
advertisers to showcase successful hair restoration results only. It is not the
mandate of this site to engage in the discussion of failed, unsuccessful
procedures, lawsuits, litigations, refunds or complaint cases. Surgical hair
restoration procedures carry risks. Please do thorough research, consult your
own physician and investigate a doctor's background carefully before making a
decision. By proceeding to use our site, you agree to abide by our Terms of Use & Privacy Policy at http://hairsite.com/terms-of-use/ where you can also find a list of HairSite's sponsoring physicians.